Mechanisms of prostate cancer cell survival after inhibition of AR expression

Journal of Cellular Biochemistry

Volumn 106, Issue 3, 2009, Pages 363-371

  Cohen, Michael H ^a   Kokhlin, Oskar W ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

ANDROGEN RECEPTOR; APOPTOSIS; CaMKII; MICRORNA 34; P53; PI3K Akt; PROSTATE CANCER

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CAMPTOTHECIN; DOXORUBICIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SURVIVAL; DNA DAMAGE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REVIEW;

ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62649133923     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22022     Document Type: Article

References (76)

1. Ambs S, Prueirt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu C-G, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM. 2008. Genomic profiling of microRNA and messenger RNA reveals deregulated nicroRNA expression in prostate cancer. Cancer Res 68:6162-6170.
2. Bergeron L, Perez GI, MacDonald G, Shi L, Sun Y, Jurisicova A, Varmuza S. 1998. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev 12:1304-1314.
3. Bode AM, Dong Z. 2004. Post-translational modification of p53 in turnor-igenesis. Nat Rev 4:793-805.
4. Chan TO, Rittenhouse SE, Tsichlis PN. 1999. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 68:965-1014.
5. Chang T-C, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26:745-752.
6. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. 2001. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20:6073-6083.
7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to anti-androgen therapy. Nat Med 10:33-39.
8. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS. 2006. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66:10613-10620.
9. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. 2007. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67:8433-8438.
10. Degterev A, Boyce M, Yuan J. 2003. A decade of caspases. Oncogene 22:8543-8567.
11. Dehm SM, Tindall DJ. 2006. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99:333-344.
12. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. 2008. Splicing of a novel androgen receptor exon generates a constitutively active andrigen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469-5477.
13. El-Deiry WS. 2001. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 8:1066-1075.
14. Ellis RE, Yuan JY, Horvitz HR. 1991. Mechanisms and functions of cell death. Annu Rev Cell Biol 7:663-698.
15. Evan GI, Vousden KH. 2001. Proliferation, cell cycle, and apoptosis in cancer. Nature 411:342-348.
16. Filipowicz W, Bhattacharyya SN, Sonenberg N. 2008. Mechanisms of post- transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 9:102-114.
17. Goldberg M, Stucki M, Falck J, D'Amours D, Rahman D, Pappin D, Jiri B, Jackson SP. 2003. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 421:952-956.
18. Graff JR. 2002. Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma. Expert Opin Ther Targets 6:103-113.
19. Gurova KV, Rokhlin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, Gudkov AV. 2002. Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 21:153-157.
20. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, Gidkov AV. 2003. Cooperation of two mutant p53 alleles contributes to Fas-resistance of prostate carcinioma cells. Cancer Res 63:2905-2912.
21. Guseva NV, Taghiyev AF, Rokhlin OW, Cohen MB. 2004. Death receptor- induced cell death in prostate cancer. J Cell Biochem 91:70-99.
22. He L, He X, Lowe SW, Hannon GJ. 2007a. MicroRNAs join the p53 network- another piece in the tumour-suppression puzzle. Nat Rev Cancer 7:819-822.
23. He X, He L, Hannon GJ. 2007b. The Guardian's little helper: MicroRNAs in the p53 tumor suppressor network. Cancer Res 67:11099-11101.
24. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. 2007c. A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134.
25. Hill MM, Hemmings BA. 2002. Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther 93:243-251.
26. Huang Z-Q, Li J, Wong J. 2002. AR possesses an intrinsic hormone-independent transcriptional activity. Mol Endocrinol 16:924-937.
27. Isaacs JT, Isaacs WB. 2004. Androgen receptor outwits prostate cancer drug. Nat Med 10:26-27.
28. Issacs WB, Carter BS, Ewing CM. 1991. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720.
29. Johnston AM, Naselli G, Gonez LJ, Martin RM, Harrison LC, DeAizpurua HJ. 2000. SPAK, a STE20/SPS1 -related kinase that activates the p38 pathway. Oncogene 19:4290-4297.
30. Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong S-M, Fu B, Lin M-T, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach S, Klein AP, Jaffee EM, Goggins M, Maitra A, lacobuzio- Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
31. Lassus P, Opitz-Araya X, Lazebnik Y. 2002. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 293:1352-1354.
32. Liao X, Tang S, Thrasher JB, Griebling T, Li B. 2005. Small-interfering RNA- induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4:505-515.
33. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TLJ, Vessella RL, Visakopri T. 2001. Amplification and over-expression of androgen receptot gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555.
34. Litvinov IV, De Marzo AM, Isaacs JT. 2003. Genetics of endocrine disease. Is the Achilles' Heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol 88:2972-2982.
35. Lou Z, Minter-Dykhouse K, Wu X, Chen J. 2003. MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature 421:957-961.
36. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L. 1998. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 58:76-83.
37. Miller CW, Aslo A, Won A, Tan M, Lampkin B, Koeffler HP. 1996. Alterations of the p53, Rb and MDM2 genes in osteosarcomas. J Cancer Res Clin Oncol 122:559-565.
38. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G. 1996. Cytoplasmic sequestration of wild-type p53 protein impairs the Gl checkpoint after DNA damage. Mol Cell Biol 16:1126-1137.
39. Murillo H, Huang H, Schmidt LJ, Smith Dl, Tindall DJ. 2001. Role of P13K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142:4795-4805.
40. Nakanishi M, Ozaki T, Yamamoto T, Kikuchi H, Furuya K, Asaka M, Delia D, Nakagawara A. 2005. NFBD1/MDC1 associates with p53 and regulates its function at the cross-roat between cell survival and death in response to DNA damage. J Biol Chem 282:22993-23004.
41. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. 2008. Widerspread deregulation of microRNA expression in human prostate cancer. Oncogene 27:1788-1793.
42. Plati J, Bucur 0, Khosravi-Far R. 2008. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J Cell Biochem 104:1124-1149.
43. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T. 2007. MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130-6135.
44. Qi H, Labrie Y, Grenier J, Fournier A, Fillion C, Labrie C. 2001. Androgens induce expression of SPAK a STE20/SPSl-related kinase, in LNCaP human prostate cancer cells. Mol Cell Endocrinol 182:181-192.
45. Rapp 1, Chen JJ. 1998. The papillomavirus E6 proteins. Biochim Biophys Acta 1378:F1-F19.
46. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. 2007. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26:731-743.
47. Reed JC. 2003. Apoptosis-targeted therapies for cancer. Cancer Cell 3:17-22.
48. Robertson JD, Gogvadze V, Kropotov A, Vakifahmetoglu H, Zhivotovsky B, Orrenius S. 2004. Processed caspase-2 can induce mitochondria-mediated apoptosis independently of its enzymatic activity. EMB0 Rep 5:643-648.
49. Rodriguez-Mora 0, LaHair MM, Howe CJ, McCubrey JA, Franklin RA. 2005. Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. Expert Opin Ther Targets 9:791-808.
50. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB. 1997. Fas- mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 57:1758-1768.
51. Rokhlin OW, Glover RA, Cohen MB. 1998. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase- 7. Cancer Res 58:5870-5875.
52. Rokhlin OW, Gudkov AV, Kwek S, Glover RA, Gewies AS, Cohen MB. 2000. p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP. Oncogene 19:1959-1968.
53. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrhu SI, Cohen MB. 2002. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther 1:631-637.
54. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Krav- chenko JE, Cohen MB. 2005. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24:6773-6784.
55. Rokhlin 0 W, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansky VE, Glover RA, Cohen MB. 2007. Calcium/calmodulin-dependent kinase 11 plays an important role in prostate cancer cell survival. Cancer Biol Ther 6:732-742.
56. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. 2008. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther 7:1288-1296.
57. Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJC, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ. 2005. Androgens and prostate cancer: Are the description valid? Cancer Biol Ther 4:4-5.
58. Rozan LM, El-Deiry WS. 2007. P53 downstream target genes and tumor suppression: A classical view in evolution. Cell Death Differ 14:3-9.
59. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. 2008. Widespread changes in protein symthesis induced by microRNAs. Nature 455:58-63.
60. Shin S, Lee Y, Kim W, Ko H, Choi H, Kim K. 2005. Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J 24:3532-3542.
61. Song JH, Bellail A, Tse MCL, Yong VW, Hao C. 2006. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci 26:3299-3308.
62. Soussi T, Dehouche K, Beroud C. 2000. p53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. Hum Mutat 15:105-113.
63. Stewart GS, Wamg B, Bignell CR, Taylor AMR. 2003. Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421:961-966.
64. Stucki M, Jackson SP. 2004. MDC1/NFBD1: A key regulator of the DNA damage response in higher eukaryotes. DNA Repair 3:953-957.
65. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H. 2007. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing. MiR-34a is a p53 target that induces apoptosis and Gl-arrest. Cell Cycle 6:1586-1593.
66. Thompson TC, Park SH, Timme TL, Ren C, Easthman JA, Donehower LA, Bradley A, Kadmon D, Yang G. 1995. Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer. Oncogene 10:869-879.
67. Tombes RM, Krystal GW. 1997. Identification of novel human tumor cell- specific CaMKII variants. Biochim Biophys Acta 1355:281-292.
68. Vasudevan S, Tong Y, Steitz JA. 2007. Switching from repression to activation: MicroRNAs can up-regulate translation. Science 318:1931-1934.
69. Vogelstein B, Lane D, Levine A. 2000. Surfing the p53 network. Nature 408:307-310.
70. Walsh JG, Cullen SP, Sheridan C, Luthi AU, Gerner C, Martin SJ. 2008. Executioner caspase-3 and caspase-7 are functionally distict proteases. Proc Natl Acad Sci USA 105:12815-12819.
71. Wang L, Whiylach LW, Flanagan JN, Flolick MF, Chen TC. 2003. Vitamin D autocrine system and prostate cancer. Recent Results Cancer Res 164:223- 237.
72. Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C. 2005. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exper Cell Res 304:244- 255.
73. Yang BF, Xiao C, Roa WH, Krammer PH, Hao C. 2003. Calcium/calmodulin- dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J Biol Chem 278:7043-7050.
74. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. 2005. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Intern 5:1-10.
75. Zhu Q, Youn H, Tang J, Tawfik 0, Dennis K, Terranova PF, Du J, Raynal P, Thrasher JB, Li B. 2008. Phosphoinositide 3-0H kinase p85a and pi 10b are essential for androgen receptor transactivation and tumor progression in prostate cancer. Oncogene 27:4569-4579.
76. Zinda MJ, Johnson MA, Paul JD, Horn C, Konicek BW, Lu ZH, Sandusky Q, Thomas JE, Neubauer BL, Lai MT, Graff JR. 2001. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 7:2475-2479.